Published in:
01-03-2021 | Gastrectomy | Original Article
Oncological outcomes in patients with pT1N0–3 or pT2–3N0 gastric cancer after curative resection without adjuvant chemotherapy
Published in: Langenbeck's Archives of Surgery | Issue 2/2021
Login to get accessAbstract
Purpose
The survival outcomes of pT1N0–3 or pT2–3N0 gastric cancer after curative resection are favorable without adjuvant chemotherapy. However, some patients develop recurrence and details of these recurrences remain unclear. This study aimed to evaluate the prognostic factors in patients with pT1N0–3 or pT2–3N0 gastric cancer.
Methods
We retrospectively reviewed the medical records of 1219 patients with pT1N0–3 or pT2–3N0 gastric cancer who underwent curative gastrectomy without neoadjuvant or adjuvant chemotherapy between April 2007 and March 2012 at Cancer Institute Hospital.
Results
This cohort included 895 pT1N0, 73 pT1N1, 23 pT1N2, 6 pT1N3, 130 pT2N0, and 92 pT3N0 patients. The 5-year overall survival (OS) and 5-year relapse-free survival (RFS) for pT1N0–3 and pT2–3N0 gastric cancer were 98.9% (95% CI 98.1–99.4) and 97.7% (95% CI 96.7–98.4), respectively. Age (HR 3.56, 95% CI 2.10–6.03) and lymphovascular involvement (hazard ratio (HR) 2.98, 95% CI 1.76–5.04) were independent prognostic factors in a multivariate analysis for RFS. The 5-year RFS for patients aged ≥75 years or with lymphovascular involvement were 94.4% (95% CI 89.8–97.0) and 95.1% (95% CI 92.5–96.8), respectively.
Conclusion
The survival outcomes of pT1N0-3 and pT2-3N0 were excellent, even in patients with aged >75 years or lymphovascular involvement which were risk factors. However, the sample size of T1N3 gastric cancer is small, so larger sample size and risk factor analysis are required.